Metropolis Healthcare (METROPOLIS) Q2 25/26 earnings summary

Executive summary

• Achieved 23% year-over-year group revenue growth for Q2 and H1 FY2026, driven by organic expansion and recent acquisitions, with margin expansion in line with guidance.

• Focused on preventive health, specialty diagnostics, and digital transformation to sustain growth.

• Integration of recent acquisitions progressing as planned, with operational efficiency and synergy realization prioritized.

• Board approved a 200% interim dividend (₹4 per share) for the period, with record date set for 11 November 2025.

• Approved unaudited standalone and consolidated financial results for Q2 and H1 FY2026, with unmodified review reports.

Financial highlights

• Q2FY26 group revenue rose 23% YoY to ₹429 Cr; H1FY26 group revenue up 23% YoY to ₹815 Cr; organic Q2FY26 revenue up 12% YoY to ₹392 Cr.

• Q2FY26 group EBITDA up 19% YoY to ₹109 Cr; PAT up 13% YoY to ₹53 Cr; organic EBITDA margin at 26.8%, group margin at 25.4%.

• Standalone revenue for Q2 FY26 was ₹35,571.32 lakhs; consolidated revenue was ₹42,919.14 lakhs.

• Standalone net profit for Q2 FY26 was ₹4,663.28 lakhs; consolidated net profit was ₹5,289.01 lakhs.

• Revenue per patient and per test increased, driven by premium offerings and higher-value packages.

Outlook and guidance

• Organic business expected to deliver 70-100 bps margin improvement over last year (24.3%), with group margin diluted by 1-1.2% due to Core Diagnostics.

• Top-line and volume growth guidance for the year maintained; double-digit volume growth (10-11%) expected for the rest of the year.

• Targeting mid-teen revenue CAGR from FY23 to FY26 and aiming to restore pre-COVID margin profile.

• No price hikes planned for the remainder of the financial year.

• No new acquisitions planned in the next 6-9 months; focus remains on organic growth and integration.